Hemmie Chang
Foley Hoag is a preeminent Life Sciences law firm that represents public and private clients in a wide range of transactions worldwide. The chair of our Licensing and Strategic Alliances practice group together with one of our leading Intellectual Property partners will be available to meet with interested companies.
Foley Hoag
Chair, Licensing & Strategic Alliances Group
Mr Dan Chicoine
Nuvo's first commercialized pain product is Pennsaid®, a non-steroidal anti-inflammatory drug (NSAID), used to treat the signs and symptoms of osteoarthritis of the knee. Pennsaid is available by prescription in the United States, Canada and several European countries. Through the acquisition of ZARS Pharma, Inc. in May 2011, the Company broadened its pain portfolio with two approved products - Pliaglis® and Synera®.
Nuvo Research Inc.
Chairman & Co-CEO
Maria Cho
Fujifilm Diosynth is a leading provider of process development and cGMP manufacturing services for biopharmaceuticals. Fujifilm Diosynth offers a proven track record in process development and cGMP manufacturing of cell culture and microbial expressed proteins, vaccines, and monoclonal antibodies. The organization has facilities in Research Triangle Park, North Carolina, USA (formerly Diosynth Biotechnology) and Billingham, UK (formerly Avecia Biologics) and was acquired by Fujifilm Corporation in April 2011. Combined, Fujifilm Diosynth brings to our clients over 25 years of experiences as a contract manufacturing organization.
Fujifilm Diosynth Biotechnologies
Director, Commercial Development
Mr Art Clapp
Created in 1981, Galderma is a joint venture between Nestlé and L'Oréal.
Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, over-the-counter drugs and aesthetic and corrective solutions) contribute to maintaining its strong leadership in dermatology.
Galderma is interested in acquiring or in-licensing products for corrective dermatology and for the treatment of acne, rosacea, onychomycosis, psoriasis, seborrheic dermatitis, atopic dermatitis, other inflammatory dermatoses, non-melanoma skin cancer, viral warts, and pigmentary disorders.
Galderma
Director - US Business Development
Ms Courtney Cote
EvaluatePharma®, leader in life science sector analysis, delivers exclusive commercial intelligence and analysis into industry performance globally.
With 10+ years’ experience and investment in our services, we provide meaningful, value-added information and analysis that aids in target identification, strategic decision-making, and risk mitigation aimed towards your competitive advantage and business results.
Our flexible, “one-stop” services include:
EvaluatePharma® featuring all the Deals Data you need for Business Development, Proprietary Data Standardization, Merge Company tool, Calendar of Events, Interactive NPV Analyzer, Sales by Indication and Consensus Forecasts for Marketed & Pipeline Products, plus much more to give you the most accurate view of the global market.
EP Clinical Trials simplifies complex analysis of the global clinical trials landscape including ClinicalTrials.gov, EudraCT and Japan clinical trials data source for trusted clinical intelligence you can rely on, and the time savings you need.
EvaluatePharma® Partnering Services make finding your next licensing partner easier, and features the latest assets available for partnering presented in their commercial context alongside our unique industry analysis.
EPVantage® renowned news service provides mapped commentary and analysis that keeps you abreast of the latest sector developments relevant to you.
Discover why EvaluatePharma is trusted and relied upon by life science companies big and small, the investment community and leading consultancies.
You can count on EvaluatePharma for:
• Product Forecasts to 2018
• New – Sales by Indication to 2018
• Product Deals
• M&A Transactions
• Product Historic Sales
• Clinical Trials
• Country Analysis
• Archived Historical Sales Forecasts
• Company profiles
• Drug Information
• R&D Pipelines
• Patent Risk
• News
• NPV’s of Marketed and Pipeline Products
• Calendar of Events - key events that will shape the future of the industry
• EP Vantage & Event Analyzer - analysis and commentary on key market events
| Partnering strategy/collaborations |
| We encourage all biotechnology companies and research organizations with developmental products available to out-license to post their licensing details to our Partnering Opportunities service. This new free service allows potential partners to see your Partnering Opportunities in their commercial context, alongside EvaluatePharma®’s unique industry analysis, including product portfolios, company financials and reference deal terms. |
| Client portfolio |
|
EvaluatePharma® has a global audience of business development and licensing professionals at the world's leading pharmaceuticals and biopharmaceuticals companies - we have Users at 85 of the top 100 pharma companies, worldwide, with more signing up every day. We look forward to meeting you at the conference! |
EvaluatePharma USA, Inc.
West Coast Manager, Sales & Solutions
Mr Jeff Davidson
Keystone Nano (KN) is a developing two nanotechnology platforms to solve problems in the treatment of cancer. Both the Ceramide NanoLiposome (CNL) and the NanoJacket (NJ) precisely deliver therapies to tumors and address a $50 billion cancer therapeutic market where single products routinely exceed a billion in sales. KN’s technology was licensed from Penn State, and is distinct from all technology in development and has substantial technological advantages. KN technology is an advanced stage of development is supported by considerable intellectual property and a successful multi-disciplinary commercialization team.
KN also creates custom nanoparticles for client companies designed to allow the creation of new products of value with highly unique features. KN has worked with a wide range of pharmaceutical clients in this manner, and can do so in a milestone based manner.
